CN111372567B - 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 - Google Patents

高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 Download PDF

Info

Publication number
CN111372567B
CN111372567B CN201880075196.7A CN201880075196A CN111372567B CN 111372567 B CN111372567 B CN 111372567B CN 201880075196 A CN201880075196 A CN 201880075196A CN 111372567 B CN111372567 B CN 111372567B
Authority
CN
China
Prior art keywords
pharmaceutical composition
solid pharmaceutical
valphenazine
valbenazine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880075196.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372567A (zh
Inventor
小理查德·亚历山大·摩尔
格雷戈里·A·麦克莱兰
克里斯托弗·F·奥勃良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111372567(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN111372567A publication Critical patent/CN111372567A/zh
Application granted granted Critical
Publication of CN111372567B publication Critical patent/CN111372567B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880075196.7A 2017-09-21 2018-09-18 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 Active CN111372567B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762561629P 2017-09-21 2017-09-21
US62/561,629 2017-09-21
US201762564951P 2017-09-28 2017-09-28
US62/564,951 2017-09-28
PCT/US2018/051579 WO2019060322A2 (en) 2017-09-21 2018-09-18 HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF

Publications (2)

Publication Number Publication Date
CN111372567A CN111372567A (zh) 2020-07-03
CN111372567B true CN111372567B (zh) 2024-03-15

Family

ID=63794661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880075196.7A Active CN111372567B (zh) 2017-09-21 2018-09-18 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒

Country Status (24)

Country Link
US (3) US20200276184A1 (enExample)
EP (1) EP3684333B1 (enExample)
JP (1) JP7250006B2 (enExample)
CN (1) CN111372567B (enExample)
AU (1) AU2018335259B2 (enExample)
BR (1) BR112020005373A2 (enExample)
CA (1) CA3076000A1 (enExample)
DK (1) DK3684333T3 (enExample)
ES (1) ES3024958T3 (enExample)
FI (1) FI3684333T3 (enExample)
HR (1) HRP20250561T1 (enExample)
HU (1) HUE071873T2 (enExample)
IL (3) IL301770B2 (enExample)
LT (1) LT3684333T (enExample)
MA (1) MA50175B1 (enExample)
MD (1) MD3684333T2 (enExample)
MX (1) MX2020002841A (enExample)
PL (1) PL3684333T3 (enExample)
PT (1) PT3684333T (enExample)
RS (1) RS66714B1 (enExample)
SI (1) SI3684333T1 (enExample)
SM (1) SMT202500305T1 (enExample)
TW (1) TWI875681B (enExample)
WO (1) WO2019060322A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN114423755A (zh) 2019-09-13 2022-04-29 纽罗克里生物科学有限公司 用于合成缬苯那嗪的方法
IL307826A (en) 2021-04-26 2023-12-01 Neurocrine Biosciences Inc Processes for the synthesis of valbanazine
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658238A (zh) * 2013-06-19 2016-06-08 索姆创新生物技术公司 用于在预防和/或治疗多动性运动障碍中使用的治疗剂
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5283918A (en) 1976-01-01 1977-07-13 Wellcome Found Pharmaceutical composition
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS6028987A (ja) 1983-07-28 1985-02-14 Chugai Pharmaceut Co Ltd 新規ジゴキシン誘導体
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
CA2487732C (en) 2002-05-28 2013-10-15 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB0307259D0 (en) 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
CN1980942A (zh) 2004-07-05 2007-06-13 索尔维亚斯股份公司 四配位基的亚铁配体及其应用
ATE415973T1 (de) 2004-10-28 2008-12-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US20110257220A1 (en) 2005-08-06 2011-10-20 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
DE102008012015A1 (de) * 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Verbesserte Isomalt-haltige Komprimate und Verfahren zu ihrer Herstellung
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
NZ594207A (en) * 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012153341A1 (en) 2011-05-12 2012-11-15 Arch Pharmalabs Limited A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
CN110200958A (zh) 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
EP2951178A4 (en) 2013-01-31 2016-07-06 Auspex Pharmaceuticals Inc VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
US20150133460A1 (en) 2013-11-11 2015-05-14 Millennium Phamaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CN106061506A (zh) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
KR20220140647A (ko) 2014-05-06 2022-10-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
MX375718B (es) 2015-02-06 2025-03-06 Neurocrine Biosciences Inc [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
WO2017084680A1 (en) 2015-11-17 2017-05-26 Rontis Hellas S.A. Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CN110691596A (zh) 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
JP2020512986A (ja) 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
EP4082546A1 (en) 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR102776189B1 (ko) 2017-11-22 2025-03-04 아시아 케미컬 인더스트리스 리미티드 발베나진의 고상 형태
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
JOP20210274A1 (ar) 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658238A (zh) * 2013-06-19 2016-06-08 索姆创新生物技术公司 用于在预防和/或治疗多动性运动障碍中使用的治疗剂
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
lNGREZZA";FDA;《FDA approved Label》;20170401;第1-16页 *
刘文.硅化微晶纤维素.《药用高分子材料学》.中国中医药出版社,2017,第76-77页. *

Also Published As

Publication number Publication date
BR112020005373A2 (pt) 2020-09-24
DK3684333T3 (da) 2025-05-12
IL273300B2 (en) 2024-06-01
PT3684333T (pt) 2025-05-08
EP3684333B1 (en) 2025-03-05
WO2019060322A3 (en) 2019-05-02
HUE071873T2 (hu) 2025-09-28
US11026939B2 (en) 2021-06-08
MD3684333T2 (ro) 2025-07-31
JP2020534305A (ja) 2020-11-26
AU2018335259B2 (en) 2024-09-12
SMT202500305T1 (it) 2025-09-12
FI3684333T3 (fi) 2025-05-13
IL309802A (en) 2024-02-01
ES3024958T3 (en) 2025-06-05
IL301770B1 (en) 2024-02-01
LT3684333T (lt) 2025-05-12
MX2020002841A (es) 2020-07-22
US20210030744A1 (en) 2021-02-04
MA50175B1 (fr) 2025-05-30
HRP20250561T1 (hr) 2025-07-04
IL301770B2 (en) 2024-06-01
IL273300B1 (en) 2024-02-01
WO2019060322A2 (en) 2019-03-28
US20200276184A1 (en) 2020-09-03
MA50175A (fr) 2021-04-21
IL273300A (en) 2020-04-30
PL3684333T3 (pl) 2025-06-23
TWI875681B (zh) 2025-03-11
CN111372567A (zh) 2020-07-03
TW201919622A (zh) 2019-06-01
SI3684333T1 (sl) 2025-06-30
EP3684333A2 (en) 2020-07-29
AU2018335259A1 (en) 2020-04-09
CA3076000A1 (en) 2019-03-28
IL301770A (en) 2023-05-01
JP7250006B2 (ja) 2023-03-31
US11311532B2 (en) 2022-04-26
US20210030743A1 (en) 2021-02-04
RS66714B1 (sr) 2025-05-30

Similar Documents

Publication Publication Date Title
CN111372567B (zh) 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
CN107921032B (zh) 用于治疗神经学疾病或病症的vmat2抑制剂
JP2021038224A (ja) 特に注意欠陥障害の治療のための方法および組成物
JP7246384B2 (ja) 遅延放出デフェリプロン錠剤及びその使用法
US20240156802A1 (en) Methods for treating disorders ameliorated by muscarinic receptor activation
MXPA06004327A (es) Composiciones y forma de dosificacion para el efecto retardado de levodopa.
EP2945626B1 (en) Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
HK40032625A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
HK40032625B (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
TWI626042B (zh) 莫達非尼於古柯鹼成癮替代治療之醫藥組成物
JP2024507264A (ja) メラトニンを含む多層ペレットの製剤
CN100431526C (zh) 一种酸敏感型药物的快速崩解片剂
BR112017027839B1 (pt) Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento
US20190151246A1 (en) Delayed-release tablets of methylphenidate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant